MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of “Hold” from Analysts

MiNK Therapeutics, Inc. (NASDAQ:INKT) has earned an average rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $35.00.

A number of research firms recently weighed in on INKT. Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. Finally, Wall Street Zen cut shares of MiNK Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th.

MiNK Therapeutics Trading Down 1.2%

MiNK Therapeutics stock opened at $11.90 on Friday. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $76.00. The stock’s fifty day simple moving average is $12.55 and its 200-day simple moving average is $13.67. The firm has a market capitalization of $55.81 million, a P/E ratio of -3.93 and a beta of 0.35.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. Sell-side analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.